IP Library Granted Patent US 8,518,439
Granted Patent B2
US 8,518,439 · App. 12/630,365 · Granted Aug 27, 2013

Liquid therapeutic composition

Inventors: Satisha Puttachari (Thane, IN); Shripad Naik (Mumbai, IN); Christopher Joseph Pulford (Lincoln, NE)
Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,518,439
App. No.
12/630,365
Granted
Aug 27, 2013
Kind
B2
Abstract

A liquid composition includes a therapeutic component dispersed in a liquid carrier system. The liquid carrier system is made up of water and a solvent. The solvent includes at least 90 wt % propylene glycol and less than 2 wt % ethanol, if ethanol is present in the solvent. The therapeutic component has acetaminophen and phenylephrine. The weight ratio of solvent to phenylephrine is between 100:1 to 2000:1. The weight ratio of solvent to acetaminophen is between 5:1 and 25:1.

Claims (33)

1. A liquid composition comprising a therapeutic component dispersed in a liquid carrier system, wherein:

the liquid carrier system comprises water and a solvent,

the solvent comprises at least 90 wt % propylene glycol and less than 2 wt % ethanol, if ethanol is present in the solvent, and

the therapeutic component comprises acetaminophen and phenylephrine,

the weight ratio of solvent to phenylephrine is between 100:1 to 2000:1, and

the weight ratio of solvent to acetaminophen is between 5:1 and 25:1.

2. The liquid composition of claim 1 , wherein the solvent comprises 95 wt % propylene glycol.

3. The liquid composition of claim 2 , wherein the solvent comprises 98 wt % propylene glycol.

4. The liquid composition of claim 3 , wherein the solvent comprises 100 wt % propylene glycol.

5. The liquid composition of claim 3 , wherein the solvent is free of ethanol.

6. The liquid composition of claim 3 , wherein the therapeutic component further comprises guaifenesin in an amount corresponding to between 0.33 wt % to 3.33 wt % of the total composition.

7. The liquid composition of claim 6 , wherein the therapeutic component further comprises a compound selected from the group consisting of dextromethorphan, diphenhydramine, brompheniramine, and pseudoephedrine.

8. The liquid composition of claim 3 , wherein phenylephrine is present in salt form wherein the salt of phenylephrine is selected from the group consisting of phenylephrine hydrochloride, phenylephrine hydrobromide, phenylephrine bitartarate, and phenylephrine tannate.

9. The liquid composition of claim 8 , wherein the therapeutic component comprises phenylephrine hydrochloride such that the weight ratio of solvent to phenylephrine hydrochloride (solvent:phenylephrine hydrochloride) is between 333:1 to 1667:1.

10. The liquid composition of claim 8 , wherein the therapeutic component comprises phenylephrine hydrochloride in an amount between 0.008 wt % to 0.08 wt % of the total composition and acetaminophen in an amount between 0.33 wt % to 6.66 wt % of the total composition.

11. The liquid composition of claim 3 , further comprising an additive selected from the group consisting of a sweetener, a flavorant, a preservative, an antioxidant, and a pH stabilizer.

12. The liquid composition of claim 3 , further comprising a flavorant and a pH stabilizer, wherein the flavorant comprises a warming flavor and the pH stabilizer is present in an amount sufficient to maintain the pH of the liquid composition in a range of between 2.0 and 5.0.

13. The liquid composition of claim 3 , wherein the liquid carrier system comprises 60 to 80 wt % water and 20 to 40 wt % of the solvent.

14. A method of treating a cold or cold-like symptoms in an individual, wherein the method comprises administering to the individual a safe and effective amount of a liquid composition comprising a therapeutic component dispersed in a liquid carrier system, wherein:

the liquid carrier system comprises water and a solvent,

the solvent comprises at least 90 wt % propylene glycol and less than 2 wt % ethanol, if ethanol is present in the solvent, and

the therapeutic component comprises acetaminophen and phenylephrine,

the weight ratio of solvent to phenylephrine is between 100:1 to 2000:1, and

the weight ratio of solvent to acetaminophen is between 5:1 and 25:1.

15. The method of claim 14 , wherein the safe and effective amount of the liquid composition is in a range between 5 ml to 30 ml of the liquid composition.

16. The method of claim 14 , wherein the individual is 12 years of age or younger.

17. A soft gelatin capsule comprising a soft gelatin shell and between 5 ml and 30 ml of a liquid composition comprising a therapeutic component dispersed in a liquid carrier system, wherein:

the liquid carrier system comprises water and a solvent,

the solvent comprises at least 90 wt % propylene glycol and less than 2 wt % ethanol, if ethanol is present in the solvent, and

the therapeutic component comprises acetaminophen and phenylephrine,

the weight ratio of solvent to phenylephrine is between 100:1 to 2000:1, and

the weight ratio of solvent to acetaminophen is between 5:1 and 25:1,

wherein the liquid composition is enclosed by the soft gelatin shell.

Assignments (4)
CHANGE OF NAME Recorded Mar 1, 2024
From: GSK CONSUMER HEALTHCARE SARL
To: HALEON CH SARL
Reel/Frame 066618/0404 →
CHANGE OF LEGAL ENTITY Recorded Apr 12, 2022
From: GSK CONSUMER HEALTHCARE S.A.
To: GSK CONSUMER HEALTHCARE SARL
Reel/Frame 059678/0841 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2020
From: NOVARTIS AG
To: GSK CONSUMER HEALTHCARE S.A.
Reel/Frame 051658/0343 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2009
From: PUTTACHARI, SATISHA; NAIK, SHRIPAD; PULFORD, CHRISTOPHER
To: NOVARTIS AG
Reel/Frame 023674/0377 →
Continuity (2)
Provisional Application 61119582 · Dec 3, 2008
Related Publication 20100136107A1 · Jun 3, 2010